To enable the application of PRS development and implementation, our eMERGE IV proposal from Partners HealthCare leverages a large biobank (>105,000 consented with genotype data on 40,000), clinical data in the electronic health records (EHR) for >4 million patients from the largest integrated health care provider in New England, advanced bioinformatics expertise, prior leadership in PRS development and state- of-the-art genetic analysis, established expertise in returning genomics results, and experience using information technology to transform clinical processes and assessing outcomes. We propose to build on our expertise to accomplish the specific aims:
Aim 1 (Discovery): Hypothesis: Polygenic risks scores will allow us to stratify eMERGE subjects based on genetic risk for common complex traits. Using the largest available genomic data resources, we will calculate and validate new PRS for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer and major depression across diverse ancestries. We will 1) compare and benchmark the performance of existing PRS construction methods in different ancestral groups, 2) develop novel statistical methods for robust trans-ethnic PRS prediction, and integrate PRS with established clinical risk factors and family history. We will obtain PRS from our network colleagues for an additional 15-e- phenotypes (total 20) with a goal of identifying high-risk individuals, e.g., top 2% of PRS risk Aim 2 (RiskInsight Report/ELSI): We will develop a ?Risk Insight Report? with clinical risk factors, family history, and PRS with evidence-based recommendations for high risk participants (top 2% of phenotype specific PRS distribution) for electronic clinical implementation. We will assess risk communication formats in our ELSI Sub-Aim 1: To test the impact and interpretability of two mock RiskInsight Reports summarizing PRS as either (a) dichotomous (defining the patient as high-risk vs intermediate/low risk) or (b) quantitative (providing a numerical estimate of the percentile of risk for the patient), with linked clinical recommendations in both cases. We will then assess, through surveys of diverse HCPs and patients, the extent to which the mock reports are understood by both HCPs and patients.
Aim 3 (Outcomes): Hypothesis: Physicians will alter their surveillance and treatment of patients based on eCDS of RiskInsight Reports. Among HCPs for high-risk subjects, we will see at least one change in clinical care after disclosure discussions with subjects. We will recruit 2500 participants for implementation of clinical PRS in RiskInsight Reports using a SMART on FHIR app for eCDS integrated with the EHR. The primary outcome will be whether any HCP took any action within 12 months after receipt of e-CDS defined by ordering screening tests, prescribing a preventive medication, or providing lifestyle advice. We will conduct analyses of the effect of disclosing results to high risk participants to determine how personalized results changed patient outcomes in laboratory values, risk reduction behaviors, or health care utilization.

Public Health Relevance

The discovery and clinical use of polygenic risk scores (PRS) for complex traits promises to dramatically change the practice of medicine. Our eMERGE IV grant will leverage a large Biobank and a rich electronic medical record to define the clinical impact of PRS derived from diverse populations and the clinical impact of returning these results along with family history and clinical risk information to participants and their healthcare providers.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01HG008685-05
Application #
9988785
Study Section
Special Emphasis Panel (ZHG1)
Program Officer
Wiley, Kenneth L
Project Start
2015-09-01
Project End
2025-04-30
Budget Start
2020-07-01
Budget End
2021-04-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Yu, Zhi; Kim, Seoyoung C; Vanni, Kathleen et al. (2018) Association between inflammation and systolic blood pressure in RA compared to patients without RA. Arthritis Res Ther 20:107
Can, Anil; Castro, Victor M; Dligach, Dmitriy et al. (2018) Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke 49:1148-1154
Mosley, Jonathan D; Feng, QiPing; Wells, Quinn S et al. (2018) A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. Nat Commun 9:3522
Chen, Chia-Yen; Lee, Phil H; Castro, Victor M et al. (2018) Genetic validation of bipolar disorder identified by automated phenotyping using electronic health records. Transl Psychiatry 8:86
Fossey, Robyn; Kochan, David; Winkler, Erin et al. (2018) Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience. J Pers Med 8:
Prado, Maria G; Iversen, Maura D; Yu, Zhi et al. (2018) Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool With or Without a Health Educator for Knowledge of Rheumatoid Arthritis Risk Factors. Arthritis Care Res (Hoboken) 70:1421-1430
Sparks, Jeffrey A; Iversen, Maura D; Yu, Zhi et al. (2018) Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial. Arthritis Care Res (Hoboken) 70:823-833
Wei, Wei-Qi; Li, Xiaohui; Feng, Qiping et al. (2018) LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation 138:1839-1849
Can, Anil; Castro, Victor M; Dligach, Dmitriy et al. (2018) Elevated International Normalized Ratio Is Associated With Ruptured Aneurysms. Stroke 49:2046-2052
Can, Anil; Rudy, Robert F; Castro, Victor M et al. (2018) Low Serum Calcium and Magnesium Levels and Rupture of Intracranial Aneurysms. Stroke 49:1747-1750

Showing the most recent 10 out of 30 publications